Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Inclusion criteria

• Women of more than 18 years old (menopause or not).
• Women with invasive breast cancer metastatic or non-metastatic, for which treatment with tamoxifen or anti-aromatase is retained.
• Cancer hormone-expressing estrogen receptor (ER) and / or progesterone receptor (PR) (≥ 10% of tumor cells in Technical HIC).
• Any previous hormonal therapy, stopped for progression, should be discontinued for at least 21 days prior to study entry.
• WHO ≤ 2.
• Women of childbearing age must use effective contraception for the duration of the study.
• Informed consent obtained and signed before any specific procedure in the study.
• Patient member in a national insurance scheme.

Exclusion criteria

• Patient with breast cancer HER2 positive (IHC and / or FISH-CISH)
• Patient already receiving hormonal therapy or patient who has not stopped hormonal therapy for at least 21 days.
• Patient that should receive a chemotherapy and / or another targeted therapy (other than hormonal therapy) for the treatment of the breast cancer.
• Any other medical or psychiatric condition or laboratory abnormality severe, acute or chronic making the inclusion of the patient in the study inappropriate in the opinion of the investigator.
• Patient unable to follow procedures, visits, examinations described in the study.
• Pregnant women or nursing mothers can not participate in the study.
• Patients under legal guardianship.